Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (CD49E)

Details for Australian Patent Application No. 2008282331 (hide)

Owner Facet Biotech Corporation

Inventors Ramakrishnan, Vanitha; Bhaskar, Vinay

Agent Davies Collison Cave

Pub. Number AU-A-2008282331

PCT Pub. Number WO2009/018226

Priority 60/952,328 27.07.07 US

Filing date 28 July 2008

Wipo publication date 5 February 2009

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/42 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against immunoglobulins (anti-idiotypic antibodies)

Event Publications

11 February 2010 PCT application entered the National Phase

  PCT publication WO2009/018226 Priority application(s): WO2009/018226

9 August 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008282338-Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

2008282318-Methods for reverting methylation by targeting DNMT3A and DNMT3B